Sponsor Track 2: Spectral Medical Sponsored Session: What is Endotoxin and Why is it Important?
Description:
Date/Time: September 27, 2023 | 1:10 - 1:40 pm ET
In 2017, the World Health Organization published a list of bacteria for which new drugs are desperately needed. The top three, Gram negative organisms, produce endotoxins as part of their outer cell membrane. Endotoxins can trigger a severe immune response in the host, leading to the release of pro-inflammatory cytokines, vascular leakage, and tissue damage. This sponsored session will describe the pathophysiology of endotoxemia and its role in sepsis. In addition, a review of the evidence of use of a novel anti-endotoxin therapy endotoxin adsorption, will be summarized.
Sponsored by Spectral Medical, Inc.
Debra Foster, BSc
Clinical Consultant
Spectral Medical
Debra M. Foster, BSc, spent 11 years as an RN in the adult critical care area. Thereafter, Debra joined the critical care clinical research team at Toronto General Hospital. She was project lead for a multi-national, multi-center clinical trial - the MEDIC study. The data was used for a successful 510(k) de novo submission to the FDA for the Endotoxin Activity Assay (EAA). It was the first IVD for sepsis. Debra went on to follow the device to its commercial partner, Spectral Medical, Inc. She became VP of Clinical Development in 2011. Debra led many clinical research projects, including the MEDIC, EUPHRATES, and TIGRIS clinical trials, aimed at endotoxin in critical illness. Currently, Debra is a clinical consultant for Spectral Medical. She has lectured to medical professionals on the topics of sepsis, endotoxin, and clinical trials for sepsis and has been a co-author of more than 50 articles in peer-reviewed journals.
Click here to register for Sepsis Alliance Summit.